Related Experiment Videos
Enzyme-linked immunosorbent assay for distinct cyclin-dependent kinase activities using phosphorylation-site-specific
Susumu Suzuki1, Katsuyuki Tamai, Shonen Yoshida
1Ina Laboratory, Medical & Biological Laboratories Co., Ltd., 1063-103 Ohara, Terasawaoka, Ina, Nagano, 396-0002, Japan.
Abstract:
Phosphorylation of retinoblastoma protein (pRB) by cyclin-dependent kinases (CDKs) at multiple sites leads to activation of transcription of cell-cycle-related genes. Cyclin/CDK complexes thus play a pivotal role in the regulation of progression from G1 to S phase. In the present study, we developed a nonradioactive, sandwich enzyme-linked immunosorbent assay (ELISA) system for measuring activities of cyclin/CDK complexes, in which the immobilized monoclonal antibody works as a trap for phosphorylated pRB containing phosphorylated amino acids at specific sites. For this purpose, we raised monoclonal antibodies that are highly specific to ppRB phosphorylated at Ser780, Thr356, or Ser612 and used them as detectors for the individual reaction products by cyclin/CDK complexes. In particular, this approach proved useful for cyclin D1/CDK4 that specifically recognizes Ser780 in pRB with only very limited phosphorylation of a conventional substrate, histone H1. The study revealed the newly developed sandwich ELISA system to have advantages over the current radioisotope assay in terms of sensitivity, precision, and rapidity. It should find application for inhibitor screening and drug discovery related to CDKs.
Insights
A new nonradioactive assay measures cyclin-dependent kinase (CDK) activity by detecting phosphorylated retinoblastoma protein (pRB). This sensitive, rapid enzyme-linked immunosorbent assay (ELISA) is ideal for CDK inhibitor screening and drug discovery.
Area of Science:
- Molecular Biology
- Biochemistry
- Cell Biology
Background:
- Cyclin-dependent kinases (CDKs) regulate cell cycle progression from G1 to S phase.
- CDK activity is controlled by phosphorylation of retinoblastoma protein (pRB) at specific sites.
- Accurate measurement of CDK activity is crucial for understanding cell cycle control and developing therapeutics.
Purpose of the Study:
- To develop a novel, nonradioactive sandwich enzyme-linked immunosorbent assay (ELISA) for quantifying cyclin/CDK complex activities.
- To create highly specific monoclonal antibodies for detecting pRB phosphorylated at key sites (Ser780, Thr356, Ser612).
- To demonstrate the utility of this ELISA system for specific CDK complexes, such as cyclin D1/CDK4.
Main Methods:
- Development of a sandwich ELISA using immobilized monoclonal antibodies to capture phosphorylated pRB.
- Generation of monoclonal antibodies specific to pRB phosphorylated at Ser780, Thr356, and Ser612.
- Application of the ELISA to measure the activity of specific cyclin/CDK complexes, including cyclin D1/CDK4.
Main Results:
- A sensitive, precise, and rapid nonradioactive sandwich ELISA system for measuring cyclin/CDK activities was successfully developed.
- The assay effectively detected pRB phosphorylation at specific sites, particularly Ser780 by cyclin D1/CDK4.
- The developed ELISA demonstrated superior performance compared to traditional radioisotope assays.
Conclusions:
- The novel sandwich ELISA offers a significant advancement for measuring cyclin/CDK activities.
- This assay system is advantageous over radioisotope methods due to its enhanced sensitivity, precision, and speed.
- The developed ELISA is well-suited for applications in CDK inhibitor screening and drug discovery.